Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Peripheral T-Lymphocyte–Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase Deficiency

1 Jan 1998

Abstract excerpt

Ten patients with adenosine deaminase deficiency (ADA-) have been enrolled in gene therapy clinical trials since the first patient was treated in September 1990. We describe a Japanese ADA- severe combined immune deficiency (SCID) patient who has received periodic infusions of genetically modified autologous T lymphocytes transduced with the human ADA cDNA containing retroviral vector LASN. The percentage of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cytomegalovirus and herpesvirus research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 9414266
DOI: 10.1182/blood.v91.1.30

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Peripheral T-Lymphocyte–Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase DeficiencyPMID 9414266Read ↗

Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decadesSemantic proximity Read ↗

Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA <sup>−</sup> Immunodeficient PatientsSemantic proximity Read ↗

T Lymphocyte-Directed Gene Therapy for ADA <sup>−</sup> SCID: Initial Trial Results After 4 YearsSemantic proximity Read ↗

Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical ManifestationsSemantic proximity Read ↗

Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapySemantic proximity Read ↗

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiencySemantic proximity Read ↗

How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID)Semantic proximity Read ↗

[Gene therapy for adenosine deaminase deficiency].Semantic proximity Read ↗

An in Vivo Model of Somatic Cell Gene Therapy for Human Severe Combined ImmunodeficiencySemantic proximity Read ↗

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.Semantic proximity Read ↗

Clinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiencySemantic proximity Read ↗

Treatment of Severe Combined Immunodeficiency Disease (SCID) due to Adenosine Deaminase Deficiency with CD34 <sup>+</sup> Selected Autologous Peripheral Blood Cells Transduced with a Human ADA Gene (Amendment). National Institutes of HealthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.